Inge Kemper

Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial

Leonie Voorwerk, Maarten Slagter, Hugo M. Horlings et al. · Nature Medicine · 2019 · 889 citations · Full text

Medicine, Immunology, Oncology +17

Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial

Mette S. van Ramshorst, Anna van der Voort, Erik van Werkhoven et al. · The Lancet Oncology · 2018 · 445 citations · Full text

Medicine, Oncology, Breast Oncology +15

Three-Year Follow-up of Neoadjuvant Chemotherapy With or Without Anthracyclines in the Presence of Dual<i>ERBB2</i>Blockade in Patients With<i>ERBB2</i>-Positive Breast Cancer

Anna van der Voort, Mette S. van Ramshorst, Erik van Werkhoven et al. · JAMA Oncology · 2021 · 144 citations · Full text

Medicine, Oncology, Breast Oncology +15

MRI-guided optimisation of neoadjuvant chemotherapy duration in stage II–III HER2-positive breast cancer (TRAIN-3): a multicentre, single-arm, phase 2 study

Anna van der Voort, Fleur M. Louis, Mette S. van Ramshorst et al. · The Lancet Oncology · 2024 · 43 citations · Full text

Medicine, Oncology, Radiology +14

Adaptive phase II randomized trial of nivolumab after induction treatment in triple negative breast cancer (TONIC trial): Final response data stage I and first translational data.

Marleen Kok, Leonie Voorwerk, Hugo M. Horlings et al. · Journal of Clinical Oncology · 2018 · 40 citations

Medicine, Immunology, Oncology +17